Cotellic (cobimetinib) — Medica

Central nervous system cancer with BRAF V600 mutation

Initial criteria

Patient is age ≥ 18 years
Medication is being used for ONE of the following: adjuvant treatment of pilocytic astrocytoma OR pleomorphic xanthoastrocytoma OR circumscribed ganglioglioma/neuroglioma/glioneuronal tumor OR recurrent/progressive high-grade glioma OR recurrent/progressive circumscribed glioma OR recurrent/progressive glioblastoma OR brain metastases due to melanoma
Patient has BRAF V600 mutation-positive disease
Medication is prescribed in combination with Zelboraf (vemurafenib tablets)

1 year